| Description |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Macter Pharma
|
Zoledronic Acid 4mg/5ml
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Fresenius kabi |
Cytarabine 500mg/50ml |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Sandoz |
|
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Sanofi |
Furosemide and amiloride 5mg |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Sandoz |
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Carboplatin 150mg/15ml |
| Content | Zoledronic acid is used to treat high levels of calcium in the blood that may be caused by certain types of cancer.
| Cytarabine is a medication used in the management and treatment of leukemias and lymphomas. It belongs to the antimetabolic group of medications. This activity reviews the indications, action, and contraindications for cytarabine as a valuable agent in treating acute myeloid leukemia (and other leukemias. | Gemcitabine is a cytidine analog with two fluorine atoms.As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells. | A combination of Furosemide and Amiloride is a diuretic which reduces the potassium loss of furosemide alone while avoiding the possible gastro-intestinal disturbances of potassium supplements.
| Oxaliplatin is a platinum based chemotherapy agent used to treat carcinoma of the colon or rectum or stage III colon cancer. | Carboplatin is an alkylating agent used to treat advanced ovarian cancer.Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
|
Reviews
There are no reviews yet.